Significant Rise in Short Interest for Evotec SE (NASDAQ:EVO) in December

Evotec SE (NASDAQ:EVO) experienced a notable increase in short interest throughout December. As of December 31st, short interest stood at 766,200 shares, which represents an impressive growth of 89.9% compared to the total of 403,500 shares reported on December 15th. At present, only 0.3% of the company's shares are sold short. Considering the average daily trading volume of 232,100 shares, the short-interest ratio is currently at 3.3 days.

Institutional Investors Show Increased Interest in Evotec

Recently, institutional investors have made adjustments to their holdings of Evotec stock. In the third quarter, Wellington Management Group LLP increased its stake in Evotec by 29.7%, owning a total of 2,634,434 shares valued at approximately $9,616,000 after acquiring an additional 602,858 shares. Novo Holdings A/S entered the fray with a new stake valued at $71,183,000 in the second quarter. Similarly, Vanguard Personalized Indexing Management LLC also acquired a new stake in Evotec worth $87,000 during the same period. DCF Advisers LLC raised its position by 140.5% in the second quarter, holding 114,953 shares valued at $552,000 after buying 67,156 additional shares. Mediolanum International Funds Ltd also purchased a new position in Evotec in the third quarter, worth around $512,000. Currently, institutional investors own about 5.81% of Evotec's stock.

Analyst Ratings on Evotec's Stock Performance

Evotec has seen several research reports assessing its stock. HC Wainwright maintained a "buy" rating while establishing a target price of $8.00 for Evotec shares in a note published on November 7th. Conversely, Jefferies Financial Group downgraded Evotec from a "buy" to a "hold" rating, lowering the target price from $8.70 to $3.80 in a report dated October 7th. Among analysts covering Evotec, one has assigned a sell rating, two recommend holding, and two suggest buying. MarketBeat's data indicates that Evotec holds a consensus rating of "Hold" alongside an average target price of $5.93.

Current Stock Performance of Evotec SE

During trading on Tuesday, shares of Evotec were down $0.10, bringing the price to $4.08. The trading volume was 49,513 shares, which is lower than the average of 59,552 shares. The company's current ratio is measured at 2.09, while the quick ratio sits at 1.99, and it has a debt-to-equity ratio of 0.43. Evotec's stock has shown a one-year low of $2.85 and a high of $8.39. The 50-day moving average price stands at $4.63, compared to the two-hundred-day moving average price of $4.12.

About Evotec SE

Evotec SE specializes as a drug discovery and development partner for the global pharmaceutical and biotechnology sectors. The company is involved in developing pharmaceutical products across a range of therapeutic areas, including autoimmune diseases, cancer, central nervous system disorders, diabetes, fibrosis, immunology, infectious diseases, kidney and liver diseases, pain management, rare conditions, respiratory diseases, tuberculosis, and women's health.

Evotec, Stock, Investors